Cargando…

A CRISPR/dCasX‐mediated transcriptional programming system for inhibiting the progression of bladder cancer cells by repressing c‐MYC or activating TP53

Detalles Bibliográficos
Autores principales:	Cao, Congcong, Yao, Lin, Li, Aolin, Zhang, Quan, Zhang, Zhenan, Wang, Xiaofei, Gan, Ying, Liu, Yuchen, Zhang, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441141/ https://www.ncbi.nlm.nih.gov/pubmed/34586743 http://dx.doi.org/10.1002/ctm2.537

Ejemplares similares

ZNF677 suppresses renal cell carcinoma progression through N6‐methyladenosine and transcriptional repression of CDKN3
por: Li, Aolin, et al.
Publicado: (2022)

Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
por: Mirgayazova, Regina, et al.
Publicado: (2020)

Evaluation of sgRNA Target Sites for CRISPR-Mediated Repression of TP53
por: Lawhorn, Ingrid E. B., et al.
Publicado: (2014)

Enhanced RNA knockdown efficiency with engineered fusion guide RNAs that function with both CRISPR-CasRx and hammerhead ribozyme
por: Zhan, Yonghao, et al.
Publicado: (2023)

Enhancement of protein translation by CRISPR/dCasRx coupled with SINEB2 repeat of noncoding RNAs
por: Cao, Congcong, et al.
Publicado: (2023)

m(6)A-mRNA Methylation Regulates Gene Expression and Programmable m(6)A Modification of Cellular RNAs With CRISPR-Cas13b in Renal Cell Carcinoma
por: Gan, Ying, et al.
Publicado: (2022)

Synthetic Artificial Long Non-coding RNA Shows Higher Efficiency in Specific Malignant Phenotype Inhibition Compared to the CRISPR/Cas Systems
por: Yao, Lin, et al.
Publicado: (2020)

CRISPR signal conductor 2.0 for redirecting cellular information flow
por: Zhan, Yonghao, et al.
Publicado: (2022)

Improving transgene expression and CRISPR‐Cas9 efficiency with molecular engineering‐based molecules
por: Zhan, Hengji, et al.
Publicado: (2020)

Transcriptome-Wide Map of N(6)-Methyladenosine Methylome Profiling in Human Bladder Cancer
por: Li, Aolin, et al.
Publicado: (2021)

CRISPR/Cas9 treatment causes extended TP53-dependent cell cycle arrest in human cells
por: Geisinger, Jonathan M, et al.
Publicado: (2020)

hTERT, MYC and TP53 deregulation in gastric preneoplastic lesions
por: Silva, Tanielly Cristina Raiol, et al.
Publicado: (2012)

Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma
por: Stolte, Björn, et al.
Publicado: (2018)

CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019)

“Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes
por: Nguyen-Khac, Florence
Publicado: (2022)

Genome‐wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild‐type TP53 and receptor tyrosine kinase genes
por: Wang, Qianqian, et al.
Publicado: (2022)

TP53-dependent toxicity of CRISPR/Cas9 cuts is differential across genomic loci and can confound genetic screening
por: Álvarez, Miguel M., et al.
Publicado: (2022)

The pan-cancer lncRNA MILIP links c-Myc to p53 repression
por: Feng, Yu Chen, et al.
Publicado: (2020)

Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
por: Haapaniemi, Emma, et al.
Publicado: (2019)

MYC, FBXW7 and TP53 copy number variation and expression in Gastric Cancer
por: Calcagno, Danielle Queiroz, et al.
Publicado: (2013)

B‐prolymphocytic leukemia (B‐PLL) with genetic aberrations involving MYC and TP53
por: Tamber, Gurdip Singh, et al.
Publicado: (2021)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Pyroptosis-Related Gene Signature Predicts the Prognosis of ccRCC Using TCGA and Single-Cell RNA Seq Database
por: Gan, Ying, et al.
Publicado: (2022)

Deletions of 9p21 and TP53 in bladder cancer.
por: Park, W. S., et al.
Publicado: (1996)

Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification
por: Lin, Xiaoyi, et al.
Publicado: (2022)

Not all predicted CRISPR–Cas systems are equal: isolated cas genes and classes of CRISPR like elements
por: Zhang, Quan, et al.
Publicado: (2017)

Myc-Induced Liver Tumors in Transgenic Zebrafish Can Regress in tp53 Null Mutation
por: Sun, Lili, et al.
Publicado: (2015)

Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system
por: Bikard, David, et al.
Publicado: (2013)

Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation
por: Tanihara, Fuminori, et al.
Publicado: (2018)

In Vitro CRISPR-Cas12a-Based Detection of Cancer-Associated TP53 Hotspot Mutations Beyond the crRNA Seed Region
por: Kohabir, Kavish A.V., et al.
Publicado: (2023)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Bacterial alginate regulators and phage homologs repress CRISPR-Cas immunity
por: Borges, Adair L., et al.
Publicado: (2020)

Oridonin promotes endoplasmic reticulum stress via TP53-repressed TCF4 transactivation in colorectal cancer
por: Zhou, Fangyuan, et al.
Publicado: (2023)

c-MYC-Induced AP4 Attenuates DREAM-Mediated Repression by p53
por: Kaller, Markus, et al.
Publicado: (2023)

AB111. Synthesizing an AND gate genetic circuit for identification of bladder cancer cells based on CRISPR-Cas9
por: Liu, Yuchen, et al.
Publicado: (2014)

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
por: Sayed, Shady, et al.
Publicado: (2022)

Repurposing endogenous type I CRISPR-Cas systems for programmable gene repression
por: Luo, Michelle L., et al.
Publicado: (2015)

Comparison of CRISPR–Cas9 Tools for Transcriptional Repression and Gene Disruption in the BEVS
por: Bruder, Mark R., et al.
Publicado: (2021)

Significance of TP53 mutation in bladder cancer disease progression and drug selection
por: Wu, Guang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cs1vh76p0i10v2nhje9uiau3g3